Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine

E G Pedersen; Anton Pottegård; Jesper Hallas; S Friis; K Hansen; P E H Jensen; David Gaist

doi:10.1111/ene.12329

Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine

E G Pedersen, Anton Pottegård, Jesper Hallas, S Friis, K Hansen, P E H Jensen, David Gaist

Department of Neurology

40 Citations (Scopus)

Abstract

The association between use of azathioprine and risk of non-melanoma skin cancer (NMSC) in patients with myasthenia was evaluated in a nationwide setting. Treatment of autoimmune myasthenia frequently involves long-term exposure to immunosuppressants, including azathioprine. Use of azathioprine increases the risk of NMSC in organ recipients and probably also in patients with other autoimmune disorders. No previous study has specifically investigated the risk of NMSC in myasthenia patients treated with azathioprine.

Original language	English
Journal	European journal of neurology : the official journal of the European Federation of Neurological Societies
Volume	21
Issue number	3
Pages (from-to)	454-58
ISSN	1351-5101
DOIs	https://doi.org/10.1111/ene.12329
Publication status	Published - 2014

Access to Document

10.1111/ene.12329

Cite this

Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine. / Pedersen, E G; Pottegård, Anton; Hallas, Jesper et al.
In: European journal of neurology : the official journal of the European Federation of Neurological Societies, Vol. 21, No. 3, 2014, p. 454-58.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{40cfa387bd8f4fbea07c1098ef67c2d3,

title = "Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine",

abstract = "The association between use of azathioprine and risk of non-melanoma skin cancer (NMSC) in patients with myasthenia was evaluated in a nationwide setting. Treatment of autoimmune myasthenia frequently involves long-term exposure to immunosuppressants, including azathioprine. Use of azathioprine increases the risk of NMSC in organ recipients and probably also in patients with other autoimmune disorders. No previous study has specifically investigated the risk of NMSC in myasthenia patients treated with azathioprine.",

author = "Pedersen, \{E G\} and Anton Potteg{\aa}rd and Jesper Hallas and S Friis and K Hansen and Jensen, \{P E H\} and David Gaist",

note = "{\textcopyright} 2013 The Author(s) European Journal of Neurology {\textcopyright} 2013 EFNS.",

year = "2014",

doi = "10.1111/ene.12329",

language = "English",

volume = "21",

pages = "454--58",

journal = "European journal of neurology : the official journal of the European Federation of Neurological Societies",

issn = "1351-5101",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "3",

}

TY - JOUR

T1 - Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine

AU - Pedersen, E G

AU - Pottegård, Anton

AU - Hallas, Jesper

AU - Friis, S

AU - Hansen, K

AU - Jensen, P E H

AU - Gaist, David

PY - 2014

Y1 - 2014

N2 - The association between use of azathioprine and risk of non-melanoma skin cancer (NMSC) in patients with myasthenia was evaluated in a nationwide setting. Treatment of autoimmune myasthenia frequently involves long-term exposure to immunosuppressants, including azathioprine. Use of azathioprine increases the risk of NMSC in organ recipients and probably also in patients with other autoimmune disorders. No previous study has specifically investigated the risk of NMSC in myasthenia patients treated with azathioprine.

AB - The association between use of azathioprine and risk of non-melanoma skin cancer (NMSC) in patients with myasthenia was evaluated in a nationwide setting. Treatment of autoimmune myasthenia frequently involves long-term exposure to immunosuppressants, including azathioprine. Use of azathioprine increases the risk of NMSC in organ recipients and probably also in patients with other autoimmune disorders. No previous study has specifically investigated the risk of NMSC in myasthenia patients treated with azathioprine.

UR - https://www.scopus.com/pages/publications/84893871133

U2 - 10.1111/ene.12329

DO - 10.1111/ene.12329

M3 - Journal article

C2 - 24330255

SN - 1351-5101

VL - 21

SP - 454

EP - 458

JO - European journal of neurology : the official journal of the European Federation of Neurological Societies

JF - European journal of neurology : the official journal of the European Federation of Neurological Societies

IS - 3

ER -

Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine

Abstract

Access to Document

Other files and links

Fingerprint

Cite this